|
 |
MiglustatThis page contains recent news articles, when available, and an overview of Miglustat but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Actelion revealed last month that the Food and Drug Administration has granted priority status to its new drug application for Zavesca (miglustat). Zenopa Tracleer drives Actelion sales up 22% - Oct 20, 2009 Ventavis (iloprost), an inhaled therapy for the treatment of PAH, leapt 57.5% to 101.6 million francs, while sales of Zavesca (miglustat), for patients ... Pharma Times Actelion Pharmaceuticals Ltd (CH) - Actelion announces 9-month financial ... - Oct 21, 2009 In the first nine months of 2009, Zavesca® (miglustat) sales were CHF 38.3 million (9M 2008: CHF 30.1 m). In local currencies, Zavesca® sales increased by ... PharmaLive.com (press release) 供应告急 åœ¨ç ”æˆˆè°¢ç—…è?¯ç¼ºå¤±æˆ?为焦点 - Oct 28, 2009 ...对那些ä¸?能è€?å?—酶替代治疗方法的患者æ?¥è¯´ï¼ŒActelion拥有一å?ªç§°ä¹‹ä¸ºç¾Žæ ¼é²?特（Miglustatã€?Zavesca）的è?¯ç‰©ï¼Œä½†æ˜¯è¿™å?ªè?¯ç‰©çš„副作用é?žå¸¸ä¸¥é‡?。 å?¥èµžå…¬å?¸å°†ä¸?å?¯èƒ½é•¿æœŸç‹¬å? ... 慧聪网 Actelion gibt Finanzergebnisse für die ersten neun Monate 2009 bekannt - Oct 20, 2009 Der Umsatz von Zavesca® (Miglustat) belief sich in den ersten neun Monaten 2009 auf CHF 38,3 Millionen (9 Monate 2008: CHF 30,1 Mio.). ... Business-News (Pressemitteilung) Actelion starts phase II tests on miglustat for cystic fibrosis... - Sep 28, 2007 ZURICH (Thomson Financial) - Actelion said it has started phase II tests on miglustat (Zavesca) for the treatment of cystic fibrosis, a genetic disorder ... Forbes PRESS RELEASE: Miglustat (Zavesca) Receives Negative Opinion from … - Oct 19, 2007 ALLSCHWIL, Switzerland, October 19, 2007 - Actelion announced today that the Committee for Medicinal Products for Human Use (CHMP) has adopted a negative ... FierceBiotech One-Year Results on the Use of Miglustat -- Zavesca -- in Niemann... - Oct 26, 2005 ALLSCHWIL, Switzerland, Oct. 26, 2005 (PRIMEZONE) -- Actelion Ltd (SWX:ATLN) (Other OTC:ALIOF) announced today a poster presentation at the annual ... primezone.com Miglustat (Systemic).(Drug overview) - Aug 1, 2006 Miglustat (MIH-glue-stat) is used to treat adults with mild to moderate type 1 Gaucher disease. Miglustat is only used in people who cannot be treated with ... Free with registration - USP DI-Volume II, Advice for the... - AccessMyLibrary.com One-Year results on the use of miglustat (Zavesca®) in Niemann-Pick … - Sep 10, 2007 ALLSCHWIL, SWITZERLAND – 30 August 2007 – Actelion Ltd (SWX: ATLN) announced today the online publication in “The Lancet Neurology “ of the one-year results ... Healthcare Republic - Healthcare Republic Miglustat (Zavesca(R)) Receives Positive Opinion From The CHMP For … - Dec 24, 2008 Actelion Ltd (SIX: ATLN) announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for an extension of ... Medical News Today - Medical News Today (press release) One-Year Results On The Use Of Miglustat (Zavesca®) In Niemann-Pick … - Aug 22, 2007 Actelion Ltd (SWX: ATLN) announced the online publication in "The Lancet Neurology" of the one-year results from a randomized controlled study evaluating ... Medical News Today - Medical News Today (press release) … Enter Into Assignment and License Agreement for Zavesca -- miglusta... - Nov 17, 2005 RR, UCB BB) today announced that the two companies have, with immediate effect, replaced their existing license agreement covering Zavesca(r) (miglustat), ... primezone.com Actelion Withdraws Its Application For An Extension Of Indication For... - Feb 25, 2008 ...by Actelion of its decision to withdraw its application for an extension of indication for the centrally authorised medicine Zavesca (miglustat). ... Medical News Today - Medical News Today (press release) Comment le miglustat agit contre la mucoviscidose - Oct 1, 2007 La kinésithérapie respiratoire, un régime alimentaire strict, les antibiothérapies et parfois une greffe de poumon peuvent prolonger et améliorer la vie des ... 20minutes.fr Actelion recovers from poor first quarter. - Aug 4, 2008 Zavesca (miglustat) was up 23% during the six-month period compared with the first half of 2007 to 19.7 million francs. ... $9.94 - Pharma Marketletter - Alacra Store 尼曼匹克症Cåž‹å?¥ä¿?ä¸?給付 - Sep 7, 2006 ...幸é?‹çš„是，å?¦ä¸€ç¨®ç½•ç—…高雪æ°?症的藥物，Miglustat作用機轉極為相似，å?¯ä»¥æŠ‘制醣脂 ... ç›®å‰?國外已經在進行Miglustat的人體實驗，但是在人體實驗未通é?Žä¹‹å‰?，衛生署ä¸? ... è?¯å?ˆæ–°è?žç¶² Actelion: Miglustat/Zavesca erhält pos. EU-Empfehlung für Niemann... - Dec 19, 2008 Allschwil (AWP) - Die Actelion hat vom europäischen Ausschuss für Humanarzneimittel (European Committee for Medicinal Products for Human Use - CHMP) einen ... Handelszeitung Online CientÃficos españoles detectan la variante de un gen que provoca la … - Oct 24, 2008 ...analÃtica y de imagen satisfactoria a miglustat y mantienen la respuesta a largo plazo con escasos efectos adversos y controlables", subrayó Giraldo. ... ADN.es Male contraception: One door opens, another closes - Nov 7, 2006 Clearly in the case of miglustat, a man is not a mouse," he adds. So with Adjudin showing positive results--but in rats--and miglustat no longer an option, ... PhysOrg.com The drug buying time for children - Nov 18, 2005 However as miglustat is a small molecule, it is able to cross the barrier and ... Miglustat, is a substrate reduction therapy that reduces the rate of ... BBC News Miglustat nella terapia di mantenimento della malattia di Gaucher di... - Jan 8, 2008 Martedì 8 Gennaio 2008 - La terapia enzimatica sostitutiva ( ERT ) con Imiglucerasi ( Cerezyme ) riduce l'epatosplenomegalia e migliora i parametri ... XagenaSalute Début de l'essai clinique Sanfilippo (MPS III) avec Miglustat (Zavesca... - Jan 17, 2007 ...souffrant de la maladie de Niemann-Pick C et de Gangliosidoses à GM2 en 2006, VML est heureuse de voir débuter un autre essai avec Miglustat (Zavesca®). ... Association Vaincre les Maladies... STF vai decidir sobre liminar que obriga MS a fornecer remédio... - Nov 16, 2005 ...a fornecer três doses diárias de 200 mg do medicamento miglustat (Zavesca) a uma criança de sete anos, portadora da doença de Niemann-Pick tipo C. ... Agora MS Tay-Sachs Disease; Zavesca trial in late onset Tay-Sachs disease … - Jan 17, 2005 The randomized open-label study is following 30 patients receiving either the current standard care for LOTS (n=10) or miglustat 200 mg 3 times a day (n=20) ... Pay-Per-View - Proteomics Weekly - Factiva, from Dow Jones Male Contraception: One Door Opens, Another Closes - Nov 12, 2006 Clearly in the case of miglustat, a man is not a mouse," he adds. So with Adjudin showing positive results--but in rats--and miglustat no longer an option, ... Medical News Today - Medical News Today (press release) Tay-Sachs Disease; Zavesca trial in late onset Tay-Sachs disease … - Jan 21, 2005 The randomized open-label study is following 30 patients receiving either the current standard care for LOTS (n=10) or miglustat 200 mg 3 times a day (n=20) ... Pay-Per-View - Genomics & Genetics Weekly - Factiva, from Dow Jones Tay-Sachs Disease; Zavesca trial in late onset Tay-Sachs disease … - Jan 22, 2005 The randomized open-label study is following 30 patients receiving either the current standard care for LOTS (n=10) or miglustat 200 mg 3 times a day (n=20) ... Pay-Per-View - Obesity, Fitness & Wellness Week - Factiva, from Dow Jones Rare genetic disorder is a double challenge for Grain Valley family - Oct 20, 2008 Maybe they could offset the cost of miglustat, the one medication that has ... Most insurers don't pay for miglustat for Niemann-Pick, because the drug is ... $2.95 - Kansas City Star - NewsBank Un nouvel espoir pour les patients - Jun 23, 2008 La molécule miglustat pourrait permettre de vaincre les troubles respiratoires ... Une molécule à l'étude, le miglustat, pourrait endiguer les troubles ... nouvelobs.com le Parisien - Archives Actualité - Archives - 01/01/1970 - Oct 2, 2007 Où en était-on de la recherche sur la mucoviscidose avant miglustat ? ... La miglustat va aller corriger le défaut de la protéine qui fonctionne mal. ... Le Parisien Zavesca may lose DOH funding - Nov 5, 2007 The Department of Health's (DOH) committee on rare diseases decided last month that there is not enough evidence showing that Miglustat, the drug marketed ... Taipei Times - Taipei Times Muco. 420.000 € et de l'espoir ! - Nov 10, 2007 Le Pr Frédéric Becq et son équipe ont découvert le miglustat en 2005. ... La conséquence d'une exposition d'une cellule pulmonaire au miglustat est une ... Le Télégramme Mathilde a besoin de vous - Jun 30, 2007 Le miglustat est un produit commercialisé pour le traitement de la maladie de Gaucher de ... Le miglustat agit en diminuant la quantité de gangliosides, ... Association Vaincre les Maladies... Maladie de Sanfilippo - Essais cliniques aux HCL - L'information... - Jun 18, 2007 Actelion Pharmaceuticals, laboratoire suisse qui commercialise pour une autre pathologie rare le miglustat (Zavesca ®), décide d'arrêter de fournir ... Rhône-Alpes-Santé.com Tests give hope for little Lucy - Nov 3, 2005 The tests, which will run for a further 12 months, show the drug, miglustat, may help to restore function in nerve cells that have been altered by the ... sunderlandtoday.co.uk Actelion Hosts its 3rd Research and Development Day - Sep 8, 2005 Line-extension studies for our two marketed products Tracleer(R) (bosentan) and Zavesca(R) (miglustat) will report data in short order until year-end. ... primezone.com … cliniques dans la maladie de Niemann-Pick de type C grâce au Miglus... - Oct 4, 2007 ...les investigateurs américains et anglais ont récemment publié les résultats de l'essai clinique de l'action du miglustat (Zavesca®) dans la maladie de ... Association Vaincre les Maladies... Olhão.com - O Portal de Guarulhos - Feb 13, 2006 Para sobreviver, o garoto precisa tomar, continuamente, o medicamento Miglustat (Zavesca), produzido por um laboratório dos Estados Unidos. ... Olhão Zavesca: une indication pour la maladie de Tay-Sachs ? - Feb 28, 2006 Décidément le miglustat, commercialisé actuellement sous le nom ZAVESCA®, semble présenter des ouvertures thérapeutiques pour nombre de maladies lysosomales ... Association Vaincre les Maladies... Factiva Search - Jan 31, 2005 ...miglustat Actelion to continue phase III trial as planned.(Brief Article). 31 January, 2005 R & D Focus Drug News. Actelion announced on 21 December 2004 ... Pay-Per-View - R & D Focus Drug News - Factiva, from Dow Jones Contraception as an Option for the Man - Nov 7, 2006 Two weeks ago, researchers at the University of Washington reported that yet another promising candidate, miglustat, which produced infertility in certain ... New York Times Factiva Search - Mar 21, 2005 ...miglustat Actelion marketed, Italy (Gaucher disease).(Pharmaceutical indutry)(Brief Article). 21 March, 2005 R & D Focus Drug News ... Pay-Per-View - R & D Focus Drug News - Factiva, from Dow Jones Men want reversible contraception ; Many feel women shouldn't bear … - Nov 14, 2006 Researchers at the University of Washington recently reported that yet another promising candidate, miglustat, which produced infertility in certain mice, ... Pay-Per-View - Chicago Tribune - ProQuest Archiver Bloomberg Printer-Friendly Page - Jun 1, 2008 ...a chronic, life-threatening disorder which severely compromises the function of the lungs and heart, Zavesca (miglustat), a small-molecule oral therapy ... Bloomberg Virades de l'Espoir: foulées solidaires au Col des Marrous - Oct 8, 2007 Depuis dix ans nous finançons l'équipe du CNRS de Poitiers dirigée par le Pr Frédéric Becq qui a découvert que la molécule du miglustat pouvait être ... ariegeNews.com 男性é?¿å•ç ”究å?–得进展 - Nov 9, 2006 ...两周å‰?，å?Žç››é¡¿å¤§å¦çš„ç ”ç©¶äººå‘˜è¯´ï¼Œå°½ç®¡ä¸€ç§?曾使人看到希望的è?¯ç‰©ç¾Žæ ¼é²?特（ ï½?ｉｇｌｕｓｔï½?ｔ）å?¯ä»¥ä½¿è€?é¼ ä¸?育，但在接å?—è¯•éªŒçš„ï¼•ä¸ªç”·äººèº«ä¸Šå®Œå…¨æ— æ•ˆã€‚ ... æ–°å?Žç½‘ Men may get birth-control options besides condoms - Jun 13, 2005 Meanwhile, the UW also is recruiting participants for an oral testosterone study and a test of a drug called Miglustat, looking at whether it inhibits the ... Seattle Post-Intelligencer - Seattle Post Intelligencer Virades de l'espoir : les dons en forte baisse par rapport à l'an... - Nov 19, 2008 Grâce à la mobilisation des bénévoles, les fonds récoltés permettent à la rechercher d'avancer : « La molécule miglustat a été testée sur une dizaine de ... La Voix du Nord 男性é?¿å•ç ”究å?–得進展 - Nov 9, 2006 ...兩周å‰?，è?¯ç››é “大å¸çš„ç ”ç©¶äººå“¡èªªï¼Œç›¡ç®¡ä¸€ç¨®æ›¾ä½¿äººçœ‹åˆ°å¸Œæœ›çš„è—¥ç‰©ç¾Žæ ¼é¯ç‰¹ï¼ˆ ï½?ｉｇｌｕｓｔï½?ｔ）å?¯ä»¥ä½¿è€?é¼ ä¸?育，但在接å?—試驗的５個男人身上完全無效。 ... æ–°è?¯ç¶² La Pierre Le Bigaut 2008. La recherche avance - Jun 26, 2008 Depuis le 28 septembre 2007, le miglustat est administré à des patients. Que pouvez-vous nous dire sur cet essai clinique ? Le projet avance bien et nous ... Le Télégramme * ל×?חר ×©× ×™×? רבות של הבטחות, חלה התקדמות מסוימת ×‘× ×™×¡×™×•× ×•×ª לפתח ×? - Nov 12, 2006 ...×œ×¤× ×™ שבועיי×? דיווחו חוקרי×? ב×?×•× ×™×‘×¨×¡×™×˜×ª ו×?×©×™× ×’×˜×•×Ÿ ×›×™ חומר × ×•×¡×£ ×©× ×—×©×‘ למבטיח, miglustat, ... ×”×?רץ le Parisien - Archives Actualité - Archives - 01/01/1970 - Jun 12, 2007 Autre maladie lysosomale : la maladie de Gaucher , pour laquelle le miglustat (Zavesca) actuellement testé sur les enfants San Filippo est utilisé. ... Le Parisien AKTIEN SCHWEIZ/Vorbörse: Schwächer - Vorgaben belasten - ABB im … - Dec 19, 2008 Das Unternehmen erhielt vom europäischen Ausschuss für Humanarzneimittel einen positiven Bescheid für eine Indikationserweiterung von Miglustat/Zavesca. ... Handelszeitung Online Stem cells have multiple brain benefits - Mar 12, 2007 Zavesca (miglustat) is now marketed by Actelion and is approved to treat Gaucher's disease - another disease caused by the build up of lipids. ... DrugResearcher.com Sem remédio, menina corre risco de morte - May 13, 2008 ...a pequena Alice Dourado de Carvalho teve o tratamento interrompido em abril, quando deixou de ingerir doses diárias do medicamento Miglustat Zavesca, ... A Tarde On Line La Pierre Le Bigaut 2008. La recherche avance - Jun 23, 2008 Depuis le 28 septembre 2007, le miglustat est administré à des patients. Que pouvez-vous nous dire sur cet essai clinique ? Le projet avance bien et nous ... Le Télégramme Actelion Announces 9-Month Results for 2005 - Oct 19, 2005 Line-extension studies for our two marketed products Tracleer(r) (bosentan) and Zavesca(r) (miglustat) will report data before year-end. ... primezone.com Actelion's 2005 revenue up 41% on Tracleer sales.(Brief Article) - Mar 6, 2006 During the period, the group's type-1 Gaucher disease medication Zavesca (miglustat) achieved sales of 14.4 million francs, skyrocketing 136%. ... $4.95 - Pharma Marketletter - ECNext Investigadores estudam novo tratamento para a fibrose cÃstica - Oct 1, 2007 O medicamento em teste utiliza a molécula miglustat para reabilitar a proteÃna CFTR, debilitada pela doença e que não cumprindo com as suas funções faz com ... Público.pt Biotechnology Pioneer Jean-Paul Clozel Named Ernst & Young World … - Jan 6, 2008 ...a chronic, life-threatening disorder which severely compromises the function of the lungs and heart, Zavesca (miglustat), a small-molecule oral therapy ... Ad-Hoc-News - Ad-Hoc-News (Pressemitteilung) Stop That Sperm! A Contraceptive Pill For Men? - Nov 21, 2007 ...blood pressure medication thought to have a contraceptive effect in some men which works by blocking the calcium channels in sperm membranes; Miglustat, ... Pharmalot Actelion's 1st-qtr 2007 loss deepens 179%.(Financial report) - Apr 30, 2007 Income from Zavesca (miglustat), the first oral treatment option for type I Gaucher disease, reached 7.5 million francs vs 5.4 million francs, though it was ... Free with registration - Pharma Marketletter - AccessMyLibrary.com Two New Gaucher Meds on Horizon - Aug 22, 2007 A similar medicine, called miglustat and marketed under the brand name Zavesca, has been available for several years, but is prescribed only to patients who ... Forward OnMedica - News: SIGN guidance on stroke and TIA, and BNF will be … - Dec 22, 2008 ...support in vascular surgery; and Zavesca (miglustat) to treat progressive neurological signs in adults and children with Niemann-Pick type C disease. ... OnMedica Article: Words of encouragement Internet blogs let family, friends... - Jul 13, 2005 Pharma Marketletter; January 15, 2009 ; 677 words ... ... a positive opinion for an extension of indication for the use of Zavesca (miglustat) in patients ... Pay-Per-View - Daily Herald - HighBeam Research Accord pour l'accès au traitement par Zavesca pour les patients... - Feb 28, 2006 Le ZAVESCA®, nom commercial du miglustat, est un produit qui a reçu une Autorisation de Mise sur le Marché par l'Agence Européenne du Médicament (EMEA) en ... Association Vaincre les Maladies... Article: NEWS AND ADVANCES IN BRIEF - Forward | HighBeam … - Aug 5, 2005 Zavesca, also known as OGT918 or miglustat, works as a substrate inhibitor to reduce the buildup of GM2 ganglioside, waste material that LOTS patients ... Pay-Per-View - Forward - HighBeam Research Competitors by Product Report - Oct 4, 2008 Actelion Ltd. (ALIOF) Products:. Zavesca (Miglustat). AEterna Zentaris Inc. (USA) (AEZS) Products:. AEZS-130/Formerly Zentaris EP-1572 (Growth Hormone ... $75.00 - Revere Reports - Revere Competitors by Product Report - Oct 11, 2008 Actelion Ltd. (ALIOF) Products:. Zavesca (Miglustat). AEterna Zentaris Inc. (USA) (AEZS) Products:. AEZS-130/Formerly Zentaris EP-1572 (Growth Hormone ... $75.00 - Revere Reports - Revere Actelion ups guidance on good 1st half.(Brief Article) - Aug 8, 2005 Zavesca (miglustat), for the treatment of mild-to-moderate type 1 Gaucher disease, contributed revenues of 5.8 million francs, compared with 2.3 million ... $4.95 - Pharma Marketletter - ECNext Drug May Prolong Lives of Tay-Sachs Babies; Trial of Zavesca, Studied... - Aug 5, 2005 Zavesca, also known as miglustat or OGT918, has for some years been in clinical trials for Late Onset Tay-Sachs, a milder, adult variation of the disease. ... Pay-Per-View - Forward - HighBeam Research Actelion's R&D day: eight compounds in pipeline.(Brief Article) - Sep 19, 2005 Class III in Europe - and Zavesca (miglustat) for the oral treatment of type 1 Gaucher disease patients not able to receive enzyme replacement as their ... $4.95 - Pharma Marketletter - ECNext Actelion's 2007 profit falls 47% on costs. - Mar 3, 2008 The turnover contribution from Actelion's Gaucher's disease drug Zavesca (miglustat) also increased, climbing 38.4% to 35.3 million francs. ... $9.94 - Pharma Marketletter - Alacra Store Actelion sees 1sr-qtr net profit leap 52%.(Brief Article) - May 2, 2005 In addition, mild-to-moderate type 1 Gaucher disease therapy Zavesca (miglustat) rocketed 200% to 2.4 million francs. Commenting on the results, ... $4.95 - Pharma Marketletter - ECNext Actelion's FY 2007 net revenues beat forecasts. - Jan 28, 2008 Income from Zavesca (miglustat), the first oral treatment option for type I Gaucher disease, reached 35.3 million francs vs 25.5 million francs. ... $9.94 - Pharma Marketletter - Alacra Store Competitors by Product Report - Oct 4, 2008 Actelion Ltd. (ALIOF) Products:. Zavesca (Miglustat). AEterna Zentaris Inc. (USA) (AEZS) Products:. AEZS-130/Formerly Zentaris EP-1572 (Growth Hormone ... $75.00 - Revere Reports - Revere Federal Register 2007 - 72 FR 30386 Draft Guidances for Industry … - May 31, 2007 Pioglitazone HCl Miglustat Mirtazapine Modafinil Moexipril HCl Montelukast Sodium Morphine Sulfate Mycophenolate Mofetil Mycophenolate Mofetil HCl N ... Pay-Per-View - Federal Register 2007 - Loislaw France's LEEM launches orphan drug campaign. - Jul 2, 2007 ...following a controversy over the cancellation of a clinical trial for Swiss biotechnology firm Actelion's Zavesca (miglustat), the first oral treatment ... $9.94 - Pharma Marketletter - Alacra Store Gaucher disease - Jun 5, 2008 Adults with type 1 Gaucher disease that cannot be treated with imiglucerase may instead be treated with miglustat, a drug taken orally that inhibits the ... Subscription - Encyclopedia Britannica Competitors by Product Report - Dec 6, 2008 Actelion Ltd. (ALIOF) Products:. Zavesca (Miglustat). AEterna Zentaris Inc. (USA) (AEZS) Products:. AEZS-130/Formerly Zentaris EP-1572 (Growth Hormone ... $75.00 - Revere Reports - Revere Biotechnologie-Pionier Jean-Paul Clozel von Ernst & Young zum World … - Jun 2, 2008 Zavesca (Miglustat), eine niedermolekulare orale Therapie für die Behandlung der Gaucher-Krankheit Typ 1, einer genetischen Störung der Lipideinlagerung ... FinancialLife Paul Clozel vence Ernst & Young World Entrepreneur - Jun 2, 2008 Zavesca (miglustat), uma pequena molécula de terapêutica oral para o tratamento da doença de Gaucher tipo 1, uma desordem genética de armazenamento de ... TVNET - TVNet L'espérance de vie des malades atteints de mucoviscidose est passée... - Jan 7, 2008 Vaincre la Mucoviscidose poursuit ses efforts d'investissement dans la recherche comme par exemple le financement des travaux sur la molécule miglustat, ... Guide des démarches Swisslatin información servicios y noticias de suiza en español - Jun 3, 2008 ...que compromete gravemente la función de los pulmones y el corazón) y Zavesca (miglustat), una terapia oral de molécula pequeña para el tratamiento de la ... Swisslatin Europese registratie van geneesmiddelen in december 2008 - Dec 23, 2008 Zavesca (miglustat) voor uitbreiding van de indicatie met behandeling van progressieve neurologische manifestaties bij volwassenen en kinderen met de ziekte ... apothekersnieuws.nl Europese registratie van geneesmiddelen in december 2008 - Dec 29, 2008 Zavesca (miglustat) voor uitbreiding van de indicatie met behandeling van progressieve neurologische manifestaties bij volwassenen en kinderen met de ziekte ... Medical facts XXIIIe édition des Virades de l'Espoir en Ariège - Sep 22, 2007 Hélène Bertrand précise «aujourd'hui nous portons beaucoup d'espoir dans le projet de l'équipe de Frédéric Beck, il est avec le «Miglustat» sur la piste ... ariegeNews.com Les virades de l'espoir, donner son souffle à la recherche… les 28 … - Sep 18, 2008 En septembre 2007, le laboratoire «Actelion» a annoncé le lancement d'un essai clinique de phase 2, pour la molécule «Miglustat», dont les résultats sont ... ariegeNews.com Pais lutam para travar doença rara - Dec 18, 2007 ...pretende avaliar os resultados do tratamento com o medicamento Miglustat (Zavesca) em 24 doentes com Mucopolissacaridose III, com idades entre os dois e ... As Beiras Online Mucoviscidose : une molécule testée sur 25 malades - Sep 28, 2007 Espagne : Le miglustat, une molécule déjà utilisée contre la maladie de Gaucher, pourrait se révéler efficace pour restaurer l'activité de la protéine CFTR, ... Cité des sciences - Cité des sciences - Edition : le bon filon Grégory Lemarchal - Oct 8, 2007 Depuis, quelques semaines, 25 patients malades testent la molécule miglustat qui entrerait dans la composition d'un médicament qui pourrait soigner les ... Le Petit Journal Crónica Social: Diario digital de Información Social - Oct 4, 2007 ...del Centro Nacional de Investigación CientÃfica de Francia (CNRS) sobre la utilización de la molécula miglustat para el tratamiento de los sÃntomas ... La Crónica Social SOLIDARITÉ mucoviscidose Une molécule qui donne de l'Espoir - Nov 28, 2007 Nous avons trouvé une molécule, la miglustat, qui permet de corriger la protéine défaillante dans la mucoviscidose. Aujourd'hui, nous commençons les essais ... Le Républicain Lorrain Tribunal determina que Ceará pague medicamento de jovem com … - Jun 11, 2007 ...do Ministério Público Federal no Ceará e determina que a União, o Estado eo municÃpio de Fortaleza forneçam a uma jovem a substância miglustat. ... Portal Verdes Mares Delegazione FFC di Ferrara - Fondazione fibrosi cistica - Dec 20, 2008 Roberto Gambari collaboratore, presso l'università di Ferrara, di due progetti di ricerca finanziati dalla Fondazione relativi al Miglustat. ... Seregno News Revue de presse du Mardi 12 juin 2007 - Jun 12, 2007 étude clinique sur une vingtaine d'enfants atteints", avec le miglustat (Zavesca®) commercialisé pour une autre maladie rare, mais il a ensuite reculé. ... Pharmaceutiques É a vez dos motards ajudarem criança de Campo de Besteiros - Mar 28, 2008 ...uma pediatra que tenta travar a evolução da doença utilizando o medicamento "zavesca – miglustat" em doentes portadores de Mucopolissacaridose. ... Jornal do Centro Santemaghreb.com_Revue de presse de la sante des pays du Maghreb - … - Sep 30, 2007 Une étude clinique de la molécule miglustat, entamée la semaine dernière, représente un "réel espoir" pour les patients atteints de mucoviscidose (maladie ... Santé Tropicale Demain, mieux traiter la mucoviscidose - Jun 19, 2008 Parmi eux, un essai avec le "Miglustat" sur 25 patients en Espagne devrait donner des résultats dès la fin de l'année 2008. ... Doctissimo |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |